Last reviewed · How we verify
Oral tablets of Alphintern®
Alphintern is a synthetic derivative of a natural compound that inhibits the activity of a specific enzyme.
Alphintern is a synthetic derivative of a natural compound that inhibits the activity of a specific enzyme. Used for Treatment of osteoarthritis, Treatment of rheumatoid arthritis.
At a glance
| Generic name | Oral tablets of Alphintern® |
|---|---|
| Sponsor | Ain Shams University |
| Drug class | Non-steroidal anti-inflammatory drug (NSAID) |
| Target | COX-2 |
| Modality | Small molecule |
| Therapeutic area | Rheumatology |
| Phase | FDA-approved |
Mechanism of action
By inhibiting this enzyme, Alphintern reduces the production of a key inflammatory mediator, thereby exerting its therapeutic effects. This mechanism is thought to contribute to its anti-inflammatory and immunomodulatory properties.
Approved indications
- Treatment of osteoarthritis
- Treatment of rheumatoid arthritis
Common side effects
- Gastrointestinal upset
- Renal impairment
- Hypersensitivity reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral tablets of Alphintern® CI brief — competitive landscape report
- Oral tablets of Alphintern® updates RSS · CI watch RSS
- Ain Shams University portfolio CI